Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tanezumab for Painful Osteoarthritis

Tanezumab for Painful Osteoarthritis Opinion EDITORIAL Jeffrey N. Katz, MD, MSc Osteoarthritis (OA) is a painful, disabling condition that treated concomitantly with tanezumab and NSAIDs than in arises from damage to cartilage, synovium, subchondral those treated with tanezumab without NSAIDs. Thus, in bone, and other joint structures. An estimated 300 mil- subsequent trials, tanezumab-treated patients have not been lion people worldwide have OA, including 30 million indi- permitted to receive NSAIDs, and those with lesions, such as viduals in the United States, subchondral insufficiency fractures or avascular necrosis, of whom more than 14 mil- which might be precursors to rapidly progressive OA, have Related article page 37 lion have symptomatic, radio- been excluded. Also, reviews of the cases of rapidly progres- graphically documented knee OA. Despite the enormous sive OA and total joint replacement occurring in tanezumab prevalence, cost, and disability associated with OA, no trials indicate that 44% of these events occurred in nonindex treatments are available to slow or reverse the inexorable joints (joints other than the one that prompted the patient destruction of joint structures that underlie the pain and to seek care). This is an important finding: A patient who disability of OA (although several agents are in various http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Tanezumab for Painful Osteoarthritis

JAMA , Volume 322 (1) – Jul 2, 2019

Loading next page...
 
/lp/american-medical-association/tanezumab-for-painful-osteoarthritis-EPreWDc64C

References (15)

Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2019.8250
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Jeffrey N. Katz, MD, MSc Osteoarthritis (OA) is a painful, disabling condition that treated concomitantly with tanezumab and NSAIDs than in arises from damage to cartilage, synovium, subchondral those treated with tanezumab without NSAIDs. Thus, in bone, and other joint structures. An estimated 300 mil- subsequent trials, tanezumab-treated patients have not been lion people worldwide have OA, including 30 million indi- permitted to receive NSAIDs, and those with lesions, such as viduals in the United States, subchondral insufficiency fractures or avascular necrosis, of whom more than 14 mil- which might be precursors to rapidly progressive OA, have Related article page 37 lion have symptomatic, radio- been excluded. Also, reviews of the cases of rapidly progres- graphically documented knee OA. Despite the enormous sive OA and total joint replacement occurring in tanezumab prevalence, cost, and disability associated with OA, no trials indicate that 44% of these events occurred in nonindex treatments are available to slow or reverse the inexorable joints (joints other than the one that prompted the patient destruction of joint structures that underlie the pain and to seek care). This is an important finding: A patient who disability of OA (although several agents are in various

Journal

JAMAAmerican Medical Association

Published: Jul 2, 2019

There are no references for this article.